Branford, Conn. July 29, 2008 CAS Medical Systems, Inc. (NASDAQ: CASM), a medical device company focused on innovative, non-invasive monitoring that is vital to patient care, today announced the placement of its one-hundredth revenue-generating FORE-SIGHT Absolute Cerebral Oximeter. The Company also announced the commercial launch and first sales of its new Neonatal/Infant Sensors.
The FORE-SIGHT monitor is the only cerebral oximeter available that provides an absolute measurement of blood oxygenation non-invasive, continuous information regarding the balance of oxygen supply and demand in the brain tissue. This immediate insight into the status of a patient’s brain oxygenation can be used by clinicians to intervene to correct inadequate saturation before deficits become critical and cause damage to the brain.
Andrew E. Kersey, President and CEO of CASMED, stated, “We are very pleased to announce these two milestone events. Each of the installed FORE-SIGHT monitors is generating recurring revenue from sales of the disposable sensors, revenue that is increasing quarter by quarter. Customers include hospitals that are new to cerebral oximetry who have recognized the importance of monitoring brain oxygen saturation, as well as those who have converted to our LASER-SIGHT® absolute measurement technology from trend-only systems.
“The commercial launch of our Neonatal/Infant sensors marks CASMED’s entrance to the important neonatal/infant cardiovascular OR and the neonatal ICU,” continued Mr. Kersey. “Demand from hospitals for the Neonatal/Infant sensors has been high since our announcement of 510(k) clearance for this application and its introduction at the American Association of Thoracic Surgeons earlier this year. Of the 40,000 infants born in the US each year with congenital heart defects, about half will require at least one invasive surgery, many in the first year of life. These babies will benefit from cerebral oximetry before, during and after surgery. CASMED’s experience in the neonatal marketplace, along with our extensive clinical results at various key hospitals, makes us uniquely positioned to take advantage of the neonatal/infant market opportunity.”
About CASMED® - Monitoring What’s Vital
CAS Medical Systems, Inc. manufactures medical devices for non-invasive patient monitoring. The Company’s newest innovative product is the FORE-SIGHT® Absolute Cerebral Oximeter the only cerebral oximeter with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.
The Company’s product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Absolute Cerebral Oximeter; the low-acuity monitoring of its full line of vital signs monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.
For further information regarding CAS Medical Systems, Inc., visit the Company’s website at www.casmed.com.
CAS Medical Systems, Inc.
Director of Corporate Communications
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, commercialization and technological difficulties, the impact of actions and events involving key customers and vendors, and other risks detailed in the Company’s Form 10-K for the year ended December 31, 2007 and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.